TacticScaleWhat Amneal Pharmaceuticals Does & How It Makes Money (AMRX)
Updated October 2026 · reflects Amneal Pharmaceuticals's latest reported financials
Generic, specialty and injectable drug maker with a government distribution arm. It earns revenue by selling generic, biosimilar, injectable and branded drugs through wholesalers, pharmacies, hospitals, managed care and government channels.
How Amneal Pharmaceuticals makes money
It earns revenue by selling generic, biosimilar, injectable and branded drugs through wholesalers, pharmacies, hospitals, managed care and government channels. It also earns distribution and packaging income through AvKARE, mostly from government customers.
What Amneal Pharmaceuticals does
Amneal Pharmaceuticals is a U.S.-based biopharmaceutical company headquartered in Bridgewater, New Jersey, founded in 2002. It has operations in the United States, India, Ireland and other markets. It reports three segments. Affordable Medicines, the generics unit, covers a wide range of dosage forms: oral solids, liquids, sterile injectables, nasal sprays, inhalation products, ophthalmics, films, transdermal patches, topicals and biosimilars. Specialty focuses on central nervous system and endocrine disorders, with Parkinson's drugs Rytary and CREXONT alongside Unithroid and ONGENTYS. The third segment, AvKARE, supplies pharmaceuticals, medical and surgical products and services mainly to government buyers such as the Department of Defense and the Department of Veterans Affairs. It also distributes products under the AvKARE and AvPAK names. Taken together, Amneal combines a high-volume generics business with a higher-margin branded neurology portfolio and a steady government distribution channel.
Products & services
- Rytary (carbidopa-levodopa)
- CREXONT
- Unithroid
- ONGENTYS
- AvKARE / AvPAK
- Generic & biosimilar portfolio
What is Amneal Pharmaceuticals worth?
On an owner-earnings DCF, Amneal Pharmaceuticals's most-likely value is about $11 versus a recent price near $20 (43% above fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$6) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
⚠ High leverage — net debt is 11.2× annual cash flow. Net debt is subtracted from this fair value, but refinancing at higher rates, principal timing, and share dilution aren’t modeled — the equity can be worth far less if cash flow weakens.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Amgen (AMGN) · Amphastar Pharmaceuticals (AMPH) · ANI Pharmaceuticals (ANIP) · AMN Healthcare Services (AMN) · Elanco Animal Health (ELAN)